Text Size

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00090519
First received: August 26, 2004
Last updated: February 25, 2011
Last verified: June 2010
History of Changes
  Purpose

The purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.


Condition Intervention Phase
Diabetic Retinopathy
 Drug: ruboxistaurin
Drug: placebo
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Mean duration of definite center of macula-involved diabetic macular edema [ Time Frame: 36 Months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Visual acuity by ETDRS visual acuity chart [ Time Frame: 36 Months ] [ Designated as safety issue: Yes ]
  • First occurrence of focal/grid photocoagulation [ Time Frame: 36 Months ] [ Designated as safety issue: Yes ]
  • Visual Function, contrast sensitivity by Pelli-Robson [ Time Frame: 36 Months ] [ Designated as safety issue: Yes ]
  • Progression of nonproliferative diabetic retinopathy by seven-field stereo fundus photography [ Time Frame: 36 Months ] [ Designated as safety issue: Yes ]
  • Development or worsening of nephropathy by glomerular filtration rate [ Time Frame: 36 Months ] [ Designated as safety issue: Yes ]
  • Development or worsening of nephropathy by albumin/creatinine ratio [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  • Visual function by the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  • Adverse events [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]

Enrollment: 737
Study Start Date: February 2004
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: ruboxistaurin
32 mg QD oral for up to 36 months
Other Names:
  • LY333531
  • Arxxant
Placebo Comparator: 2 Drug: placebo
QD oral for up to 36 months

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 or Type 2 diabetes
  • 18 years or older
  • Non-clinically significant diabetic macular edema
  • Mild to moderate diabetic retinopathy in the study eye, vitreous hemorrhage in the study eye
  • Relatively good vision (20/30 or better)

Exclusion Criteria:

  • Surgery or laser treatment in the study eye
  • Glaucoma in the study eye
  • HA_I_C greater than 11%, or systolic blood pressure greater than 170 mm Hg
  • Liver disease, dialysis or renal transplant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00090519

  Show 84 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
Lilly Clinical Trial Registry  This link exits the ClinicalTrials.gov site

No publications provided by Eli Lilly and Company

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Chief Medical Officer, Eli Lilly
ClinicalTrials.gov Identifier: NCT00090519     History of Changes
Other Study ID Numbers: 8211, B7A-MC-MBDL
Study First Received: August 26, 2004
Last Updated: February 25, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetic Retinopathy
Macular Edema
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
 Diabetes Mellitus
Endocrine System Diseases
Macular Degeneration
Retinal Degeneration
Ruboxistaurin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013